MedPath

Special Drug Use-results survey for long term administration of Reminyl 4mg/8mg/12mg Tablets, 4mg/8mg/12mg OD Tablets, 4mg/mL Oral Solutio

Not Applicable
Conditions
Mild to moderately severe dementia of the Alzheimer&#39
s type
Registration Number
JPRN-UMIN000017151
Lead Sponsor
Janssen Pharmaceutical K.K.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
600
Inclusion Criteria

Not provided

Exclusion Criteria

NA

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety (Adverse Drug Reactions) Efficacy (Mini-Mental State Examination, Clinical Global Impression-Improvement scale, Medication Satisfaction Questionnaire of caretaker)
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath